Introduction
Treatment of Localized Diseases
Surgery
Radiotherapy
Study |
N
| Treatment | Local recurrence | DFS (5 years) | OS (5 years) |
---|---|---|---|---|---|
Rosenberg et al. [14] | 43 | LSS + postoperative RT | 14.8% | 71% | 83% |
Amputation | 0% | 78% | 88% | ||
P = 0.06 |
P = 0.75 |
P = 0.99 | |||
Yang et al. [23] | 141 | LSS + postoperative RT | 0.01% | NR | 75%b
|
LSS | 23.9% | NR | 74%b
| ||
P = 0.0001 |
P = 0.71 | ||||
Pisters et al. [24] | 119 | Surgery + brachytherapy | 16.7% | 83%a
| 84%c
|
Surgery | 29% | 76%a
| 81%c
| ||
P = 0.04 |
P = 0.60 |
P = 0.65 | |||
O’Sullivan et al. [31] | 190 | Preoperative RT (50 Gy) | 7% | 58% | 73% |
Postoperative RT (66 Gy) | 8% | 59% | 67% | ||
P = 0.48 |
P = 0.48 |
P = 0.48 |
Chemotherapy
Study | No. of trials | No. of patients | Regimen | Doxorubicin and ifosfamide dosage | Local recurrence | Distant recurrence | Overall recurrence | Overall survival |
---|---|---|---|---|---|---|---|---|
1997 sarcoma meta-analysis collaboration [34] | 14 | 1568 | Doxorubicin alone (n = 6) Doxorubicin + other chemotherapy drugs (n = 7) Doxorubicin + ifosfamide + DTIC (n = 1) | Doxorubicin: 50–70 mg/m2 per cycle Ifosfamide: 1500 mg/m2 per cycle | HR = 0.73 (95% CI 0.56–0.94) P = 0.016 | HR = 0.70 (95% CI 0.57–0.85) P = 0.0003 | HR = 0.75 (95% CI 0.64–0.87) P = 0.0001 | HR = 0.89 (95% CI 0.76–1.03) P = 0.12 |
2008 updated meta-analysis [35] | 18 | 1953 | Doxorubicin alone (n = 6) Doxorubicin + other chemotherapy drugs (n = 7) Doxorubicin + ifosfamide (n = 5) | Doxorubicin: 50–70 mg/m2 per cycle Ifosfamide: 1500–5000 mg/m2 per cycle | OR = 0.73 (95% CI 0.56–0.94) P = 0.02) | OR = 0.67 (95% CI 0.56–0.82) P = 0.0001 | OR = 0.67 (95% CI 0.56–0.82) P = 0.0001 | HR = 0.77 (95% CI 0.64–0.93) P = 0.01 |
Pooled analysis of EORTC-STBSG clinical trials [37] | 2 | 819 | Doxorubicin + other chemotherapy drugs (n = 1) Doxorubicin + ifosfamide (n = 1) | Doxorubicin: 50–75 mg/m2 per cycle Ifosfamide: 5 g/m2
| NR | NR | HR = 0.74 (95% CI 0.60–0.92) P = 0.0056 | NS |